Pharmacoepidemiology and Drug Safety Lead | RWE Team Leader | Angel investor | Startup advisor

Currently working in IQVIA which is the merger of former Quintiles and IMS Health, I joined the latter before the merger in 2011 to build its actual offer in pharmacoepidemiology and drug safety in the context of the then upcoming pharmacovigilance regulation released by the European Medicines Agency (EMA). In this role, I developed the “Epidemiology, Safety and Risk Management” activity of the company from business plan to hiring people and direct involvement in business development, bidding, designing, and conduct of post-authorization safety studies (PASS), comparative effective research (CER), drug utilization studies (DUS), surveys and systematic reviews. Currently, through a network of 18 people across Europe (the Centre of Excellence), we commercialize and implement robust multi-country studies designed and conducted to comply with the requirements of EMA, competent authorities and health technology assessment (HTA) bodies. We conduct studies based on both primary data collection, databases (claims, EMR, registries, etc) and hybrid methods.
A highly connected person, I consider myself as a salesman of ideas, solutions and talents, acting in a highly scientific market. I lead a work stream in the Database special interest group in the International Society of Pharmacoepidemiology (ISPE), and represent my company in the European Network of Centers for Pharmacoepidemiology and Pharmacovigilance (ENCePP), HTA International (HTAi), and the International Society of Pharmacoeconomic and Outcomes Research (ISPOR). I am also a member of the Editorial Board of the American Medical Journal.